Imagine a thief that sneaks into a vault through a back door — and scientists just found the lock. Researchers at Ohio State University in Columbus have discovered a way to make one of the deadliest brain cancers more vulnerable to treatment, potentially opening a new path forward for patients who currently have few options. Glioblastoma is an aggressive cancer that forms in the brain, and standard treatments like radiation and chemotherapy often stop working because the tumors adapt and survive. The disease affects thousands of people each year, and survival rates remain low. But a new study offers a glimmer of hope. The Ohio State team found that blocking a protein called SET makes glioblastoma cells much easier to kill with radiation. In laboratory and animal tests, suppressing SET actually prevented tumors from forming at all. The researchers focused on an enzyme called PP2A, which helps control the signals that let cancer cells grow, survive, and repair themselves after treatment. Glioblastoma cells appear to block PP2A using three proteins — ANP32A, CIP2A, and SET. When the scientists blocked these proteins, cancer cell survival dropped and the cells grew more sensitive to radiation. "Glioblastoma is hard to treat because it can adapt and survive," said Dr. Arnab Chakravarti, chair of radiation oncology at the OSUCCC–James cancer center. "Our findings suggest that restoring PP2A activity may make glioblastoma cells less able to survive treatment." The team even tested an existing FDA-approved antipsychotic drug that can increase PP2A activity, showing that this pathway could potentially be targeted with drugs. However, researchers stress this work is in early stages — it has only been tested in labs and animals, not in patients. The next step is determining whether blocking SET and related proteins is safe for people, and whether it actually improves outcomes when combined with standard treatment. "This is an important first step," Chakravarti said. The hope is that one day, adding a drug that unblocks PP2A could make radiation and chemotherapy work better — giving patients more time and better quality of life.